220 related articles for article (PubMed ID: 23746537)
1. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
Strang AC; Bisoendial RJ; Kootte RS; Schulte DM; Dallinga-Thie GM; Levels JH; Kok M; Vos K; Tas SW; Tietge UJ; Müller N; Laudes M; Gerlag DM; Stroes ES; Tak PP
Atherosclerosis; 2013 Jul; 229(1):174-81. PubMed ID: 23746537
[TBL] [Abstract][Full Text] [Related]
2. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
4. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.
McInnes IB; Thompson L; Giles JT; Bathon JM; Salmon JE; Beaulieu AD; Codding CE; Carlson TH; Delles C; Lee JS; Sattar N
Ann Rheum Dis; 2015 Apr; 74(4):694-702. PubMed ID: 24368514
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
Saiki O; Uda H
Rheumatol Int; 2018 Dec; 38(12):2307-2313. PubMed ID: 30206670
[TBL] [Abstract][Full Text] [Related]
6. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
[TBL] [Abstract][Full Text] [Related]
7. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
8. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
9. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
11. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
12. Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.
Ferraz-Amaro I; Hernández-Hernández MV; Tejera-Segura B; Delgado-Frías E; Macía-Díaz M; Machado JD; Diaz-González F
Horm Metab Res; 2019 Mar; 51(3):200-209. PubMed ID: 30695794
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
15. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
Kawashiri SY; Kawakami A; Yamasaki S; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Ida H; Origuchi T; Ueki Y; Eguchi K
Rheumatol Int; 2011 Apr; 31(4):451-6. PubMed ID: 20024554
[TBL] [Abstract][Full Text] [Related]
16. Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy.
Hu W; Ding Y; Guan K; Zhang P; Su J; Zhang C; Li W; Lian C; Yang Q; Liu S; Li T
Clin Rheumatol; 2024 Jun; 43(6):1845-1853. PubMed ID: 38696116
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H
Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.
Dessein PH; Stanwix AE; Joffe BI
Arthritis Res; 2002; 4(5):R5. PubMed ID: 12223108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
